RAMM Pharma Corp. (CSE: RAMM)
Canada
· Delayed Price · Currency is CAD 0.0200
0.00 (0.00%)
Sep 24, 2024, 9:30 AM EDT
RAMM Pharma Income Statement
Financials in millions CAD. Fiscal year is November - October.
Millions CAD. Fiscal year is Nov - Oct.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '24 Apr 30, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 | Oct '20 Oct 31, 2020 | Oct '19 Oct 31, 2019 | 2018 |
| Revenue | 4.59 | 5.07 | 3.9 | 4.12 | 5.44 | 5.61 | Upgrade
|
| Revenue Growth (YoY) | -1.59% | 29.96% | -5.31% | -24.40% | -2.96% | -32.77% | Upgrade
|
| Cost of Revenue | 4.35 | 4.68 | 3.41 | 4.15 | 4.17 | 4.84 | Upgrade
|
| Gross Profit | 0.24 | 0.38 | 0.48 | -0.04 | 1.27 | 0.77 | Upgrade
|
| Selling, General & Admin | 7.36 | 7.47 | 8.42 | 6.6 | 8.85 | 2.69 | Upgrade
|
| Other Operating Expenses | -0.01 | - | - | - | - | - | Upgrade
|
| Operating Expenses | 7.35 | 7.47 | 8.42 | 6.6 | 8.85 | 2.69 | Upgrade
|
| Operating Income | -7.11 | -7.09 | -7.94 | -6.64 | -7.58 | -1.92 | Upgrade
|
| Interest Expense | -0.04 | -0.05 | -0.01 | -0.01 | -0.06 | -0.46 | Upgrade
|
| Interest & Investment Income | 0.15 | 0.2 | 0.16 | 0.37 | 0.33 | - | Upgrade
|
| Earnings From Equity Investments | - | - | - | -0.71 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.05 | -0.04 | 0.08 | -0.3 | -0.13 | -0.66 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.79 | 0.35 | 0.17 | 0.03 | - | 0 | Upgrade
|
| EBT Excluding Unusual Items | -7.84 | -6.64 | -7.54 | -7.26 | -7.43 | -3.04 | Upgrade
|
| Impairment of Goodwill | - | - | -12.93 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -0.23 | 0.27 | - | - | Upgrade
|
| Asset Writedown | -1.07 | -1.07 | -0.25 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | -0.11 | - | -3.78 | Upgrade
|
| Pretax Income | -8.91 | -7.71 | -20.95 | -7.1 | -7.43 | -6.81 | Upgrade
|
| Income Tax Expense | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0.01 | Upgrade
|
| Net Income | -8.92 | -7.72 | -20.96 | -7.11 | -7.43 | -6.82 | Upgrade
|
| Net Income to Common | -8.92 | -7.72 | -20.96 | -7.11 | -7.43 | -6.82 | Upgrade
|
| Shares Outstanding (Basic) | 120 | 121 | 123 | 108 | 101 | 50 | Upgrade
|
| Shares Outstanding (Diluted) | 120 | 121 | 123 | 108 | 101 | 50 | Upgrade
|
| Shares Change (YoY) | -2.10% | -1.41% | 13.20% | 7.86% | 99.46% | 0.83% | Upgrade
|
| EPS (Basic) | -0.07 | -0.06 | -0.17 | -0.07 | -0.07 | -0.14 | Upgrade
|
| EPS (Diluted) | -0.07 | -0.06 | -0.17 | -0.07 | -0.07 | -0.14 | Upgrade
|
| Free Cash Flow | -4.33 | -4.45 | -6.08 | -4.26 | -3.19 | -2.2 | Upgrade
|
| Free Cash Flow Per Share | -0.04 | -0.04 | -0.05 | -0.04 | -0.03 | -0.04 | Upgrade
|
| Gross Margin | 5.25% | 7.54% | 12.43% | -0.91% | 23.40% | 13.66% | Upgrade
|
| Operating Margin | -154.81% | -139.90% | -203.64% | -161.37% | -139.14% | -34.25% | Upgrade
|
| Profit Margin | -194.21% | -152.43% | -537.79% | -172.66% | -136.47% | -121.56% | Upgrade
|
| Free Cash Flow Margin | -94.36% | -87.86% | -156.02% | -103.52% | -58.61% | -39.15% | Upgrade
|
| EBITDA | -6.32 | -6.04 | -7 | -6.01 | -7.24 | -1.9 | Upgrade
|
| EBITDA Margin | -137.65% | -119.18% | -179.69% | -145.94% | -132.89% | -33.94% | Upgrade
|
| D&A For EBITDA | 0.79 | 1.05 | 0.93 | 0.63 | 0.34 | 0.02 | Upgrade
|
| EBIT | -7.11 | -7.09 | -7.94 | -6.64 | -7.58 | -1.92 | Upgrade
|
| EBIT Margin | -154.81% | -139.90% | -203.64% | -161.37% | -139.14% | -34.25% | Upgrade
|
| Advertising Expenses | - | 0.2 | 0.42 | 0.09 | 0.08 | 0.08 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.